Atezolizumab (Tecentriq)

Abstract


 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses atezolizumab for injection (Tecentriq), solution for IV infusion, 1,200 mg/20 mL.
 Indication: In combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer.